Company Profile

DelMar Pharmaceuticals is a clinical and commercial stage drug development company with a focus on the treatment of cancer.

We are conducting clinical trials in the United States with our product candidate, VAL-083, as a potential new treatment for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

We have also acquired certain exclusive commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer.

Stock Snapshot

DMPI
0.52
OTCQX
3:27 PM EDT Aug 3, 2015
Market cap
Volume
Change
18.66M
43.5k
0.01 (0.92%)
View Detailed Stock Data VIEW